Survey Shows Gaps In CoA Monitoring; FDA Sees Guidance, Tracking As Fixes
This article was originally published in The Gray Sheet
Executive Summary
FDA says it is monitoring newly implemented measures aimed at bolstering design, execution and completion of Condition of Approval (CoA) studies